Access Economics was commissioned by Eli Lilly to estimate the economic costs of Heart Attack and Chest Pain (Acute Coronary Syndrome-ACS) in Australia for 2009. In addition, an objective was to investigate current gaps in ACS treatment and clinical need, and highlight areas of treatment where further investment may result in significant benefits through a reduction in the burden of disease and improvements in efficiency and quality of care.
|Publisher||Access Economics Pty Limited|
|Commissioning body||Eli Lilly Australia Pty Ltd|
|Number of pages||88|
|Publication status||Published - Jun 2009|